Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 07h01 HE | Source: Research and Markets

Low-Grade Glioma Market Trends and Investment Opportunities Through 2030 & 2035: Regional Insights for Trametinib, Dabrafenib, Ivosidenib, and Mirdametinib

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Low-Grade Glioma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global low-grade glioma market is experiencing a...
02 avr. 2026 07h01 HE | Source: Adagene Inc.

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide...
02 avr. 2026 07h00 HE | Source: Wix.com, Ltd.

Wix Announces Preliminary Results of Modified Dutch Auction Tender Offer

Wix announces the preliminary results of its “modified Dutch Auction” tender.
02 avr. 2026 07h00 HE | Source: Aurora Mobile Limited

Aurora Mobile Unveils 500% Efficiency Boost Case Study at Tourism × Web3 Summit 2026

SINGAPORE, April 02, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading provider of customer engagement and marketing technology services, is...
02 avr. 2026 07h00 HE | Source: Neutrolis, Inc.

Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrationsNTR-1011 displayed a predictable...
02 avr. 2026 07h00 HE | Source: Scotts Miracle-Gro Company (The)

ScottsMiracle-Gro Reaffirms Fiscal 2026 Guidance; Margin Recovery and Growth Plans Remain on Track

MARYSVILLE, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, announced that it...
02 avr. 2026 07h00 HE | Source: Plug Power, Inc.

Plug Power Selected to Supply a 275 MW GenEco Electrolyzer System for Hy2gen’s Courant Decarbonized Ammonium Nitrate Project in Baie-Comeau, Québec, Canada

SLINGERLANDS, N.Y., April 02, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced it has been awarded the Front-End...
02 avr. 2026 07h00 HE | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced...
02 avr. 2026 07h00 HE | Source: OTC Markets

OTC Markets Group Welcomes Vallant Financial Inc. to OTCQX

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vallant...
02 avr. 2026 07h00 HE | Source: Lightbridge Corporation

Lightbridge to Participate at Upcoming Investor Conferences

RESTON, Va., April 02, 2026 (GLOBE NEWSWIRE) -- Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that President...

Page suivante